ATE408693T1 - Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff - Google Patents

Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff

Info

Publication number
ATE408693T1
ATE408693T1 AT00941614T AT00941614T ATE408693T1 AT E408693 T1 ATE408693 T1 AT E408693T1 AT 00941614 T AT00941614 T AT 00941614T AT 00941614 T AT00941614 T AT 00941614T AT E408693 T1 ATE408693 T1 AT E408693T1
Authority
AT
Austria
Prior art keywords
piv
vaccine
genome
parainfluenza virus
bovine
Prior art date
Application number
AT00941614T
Other languages
English (en)
Inventor
Alexander Schmidt
Mario Skiadopoulos
Peter L Collins
Brian Murphy
Jane Bailly
Anna Durbin
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE408693T1 publication Critical patent/ATE408693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00941614T 1999-07-09 2000-06-16 Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff ATE408693T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14313499P 1999-07-09 1999-07-09

Publications (1)

Publication Number Publication Date
ATE408693T1 true ATE408693T1 (de) 2008-10-15

Family

ID=22502741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941614T ATE408693T1 (de) 1999-07-09 2000-06-16 Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff

Country Status (12)

Country Link
EP (3) EP2019141A3 (de)
JP (1) JP4813711B2 (de)
KR (1) KR100940776B1 (de)
CN (2) CN101392239A (de)
AT (1) ATE408693T1 (de)
BR (1) BR0013190A (de)
CA (1) CA2378661A1 (de)
DE (1) DE60040289D1 (de)
ES (1) ES2312347T3 (de)
IL (2) IL147167A0 (de)
MX (1) MXPA01013302A (de)
WO (1) WO2001004320A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
CN102766605A (zh) * 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001271909A1 (en) * 2000-07-05 2002-01-14 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US7704509B2 (en) 2001-11-21 2010-04-27 United States Of America Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP4553589B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー 組換えパラインフルエンザウイルス発現系とメタニューモウイルスから得られる異種抗原を含むワクチン
CA2499404A1 (en) 2002-09-18 2004-04-01 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Recovery of recombinant human parainfluenza virus type 2 (hpiv2) from cdna and use of recombinant hpiv2 in immunogenic compositions and as vectors to elicit immune responses against piv and other human pathogens
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
JP2006524511A (ja) * 2003-04-25 2006-11-02 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス由来の異種抗原を含む組換えパラインフルエンザウイルス発現系およびワクチン
US7704720B2 (en) 2003-04-25 2010-04-27 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
AU2004250129A1 (en) 2003-06-09 2004-12-29 Wyeth Improved method for the recovery of non-segmented, negative-stranded RNA viruses from cDNA
CN107818197B (zh) * 2017-09-15 2021-05-25 南京航空航天大学 一种基于piv技术的超声速翼型的测力方法和装置
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN113322241B (zh) * 2021-05-14 2023-06-13 金宇保灵生物药品有限公司 一种牛副流感病毒3型病毒株bpiv3-nm及其应用
CN116676275B (zh) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A基因型嵌合腮腺炎病毒株和制备方法及用途
WO2025106787A1 (en) 2023-11-17 2025-05-22 Sanofi Pasteur Inc. Trehalose vaccine formulation
CN118909958B (zh) * 2024-07-25 2025-02-07 中国兽医药品监察所 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CN1285608C (zh) * 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
BR9710363A (pt) 1996-07-15 2000-01-11 Us Gov Health & Human Serv "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante"
KR100702523B1 (ko) * 1997-05-23 2007-04-04 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클로닝된 뉴클레오타이드 서열로부터 약독화된파라인플루엔자 바이러스를 제조하는 방법

Also Published As

Publication number Publication date
MXPA01013302A (es) 2004-03-10
EP1194564B1 (de) 2008-09-17
EP2019141A2 (de) 2009-01-28
CN1369011A (zh) 2002-09-11
CN100402651C (zh) 2008-07-16
EP1194564A1 (de) 2002-04-10
WO2001004320A1 (en) 2001-01-18
EP2019140A3 (de) 2009-02-04
IL147167A0 (en) 2002-08-14
EP2019140A2 (de) 2009-01-28
KR100940776B1 (ko) 2010-02-11
BR0013190A (pt) 2002-07-16
CA2378661A1 (en) 2001-01-18
KR20020022768A (ko) 2002-03-27
ES2312347T3 (es) 2009-03-01
IL147167A (en) 2010-06-16
JP4813711B2 (ja) 2011-11-09
CN101392239A (zh) 2009-03-25
JP2003504064A (ja) 2003-02-04
EP2019141A3 (de) 2009-02-04
DE60040289D1 (de) 2008-10-30

Similar Documents

Publication Publication Date Title
ATE408693T1 (de) Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE509097T1 (de) Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
DE69535680D1 (de) Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika
ATE366314T1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
BR9807873A (pt) Vacinas de flavivìrus quiméricos
DE69206631D1 (de) Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
CY1107786T1 (el) Συστηματα εκφρασεως και εμβολια ανασυνδυασμενου ιου rsv
DK513388A (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
EP1572947A4 (de) GEWINNUNG VON REKOMBINANTEM HUMANEM PARAINFLUENZA-VIRUS TYP 2 (HPIV2) AUS cDNA UND VERWENDUNG VON REKOMBINANTEM HPIV2 IN IMMUNOGENEN ZUSAMMENSETZUNGEN SOWIE ALS VEKTOREN ZUR HERVORRUFUNG VON IMMUNREAKTIONEN GEGEN PIV UND ANDERE MENSCHLICHE KRANKHEITSERREGER
WO2005014626A3 (en) Recombinant human metapneumovirus and its use
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
WO2009051823A3 (en) Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
DE60029327D1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
ATE389021T1 (de) Rrekombinante proteine eines pakistani-stammes von hepatitis-e-virus, ihre verwendung in diagnotischen verfahren und als impfstoff
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee